| dc.creator | Reis L.O. | |
| dc.date | 2012 | |
| dc.date | 2015-06-26T20:30:35Z | |
| dc.date | 2015-11-26T14:31:26Z | |
| dc.date | 2015-06-26T20:30:35Z | |
| dc.date | 2015-11-26T14:31:26Z | |
| dc.date.accessioned | 2018-03-28T21:34:48Z | |
| dc.date.available | 2018-03-28T21:34:48Z | |
| dc.identifier | | |
| dc.identifier | Endocrine-related Cancer. , v. 19, n. 3, p. R93 - R98, 2012. | |
| dc.identifier | 13510088 | |
| dc.identifier | 10.1530/ERC-12-0040 | |
| dc.identifier | http://www.scopus.com/inward/record.url?eid=2-s2.0-84862641659&partnerID=40&md5=f6b7dd245c2c7fa6582cb492522302f0 | |
| dc.identifier | http://www.repositorio.unicamp.br/handle/REPOSIP/97380 | |
| dc.identifier | http://repositorio.unicamp.br/jspui/handle/REPOSIP/97380 | |
| dc.identifier | 2-s2.0-84862641659 | |
| dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1247367 | |
| dc.description | The hypothesis 'the lower the better when achieving castration levels of testosterone' is based on the data from second-line hormonal manipulation and its molecular basis, and on better oncological results reported for lower castration levels in prostate cancer (PCa) patients, including those achieved with maximal androgen blockade. In this regard, the equivalence of surgical and different pharmacological castrations has been controversial. The modified amino acid structure that makes LH-releasing hormone (LHRH) analogs more potent than LHRH, and the method of delivering the analogs impacts on bioavailibility and potentially causes differences in androgen levels and in its final oncological efficacy. In addition to this, there is a myriad of circumstances, such as those related to ethnic variations and co-morbidities, which uniquely impact on the pharmacological approach in a highly heterogeneous population of castration-resistant prostate cancer (CRPC) patients. Ineffective testosterone suppression through hormonal escape is currently poorly recognized and may result in increased PCa mortality. Until now, the optimal serum testosterone level in patients under castration, and the impact of its variations in patients under LHRH therapy, remain open questions and have been merged to a broad spectra of patients who are highly heterogeneous. This heterogeneity relates to a number of mechanisms regarding response to treatment, which influences the biology of the relapsing tumor and the sensitivity to subsequent therapies in the individual patient. The rationale to achieve testosterone levels below 20-50 ng/dl warrant further investigation as these levels have recently rescued CRPC patients. In the last few years and months, important advancements in prostate cancer treatment have been achieved. Nevertheless, these advances are measured in a few months of additional survival and under high costs, not available to most of the world population, compared with the benefits of hormonal manipulation that are measured in years, there is a huge potential for accessible and durable effect expansion and optimization of treatment, particularly with the current tendency of a more individual approach. © 2012 Society for Endocrinology. | |
| dc.description | 19 | |
| dc.description | 3 | |
| dc.description | R93 | |
| dc.description | R98 | |
| dc.description | Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J.B., Mirimanoff, R.O., Storme, G., Sternberg, C., Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial (2002) Lancet, 360, pp. 103-106. , doi:10.1016/ S0140-6736(02)09408-4 | |
| dc.description | Chodak, G.W., Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma (1989) Urology, 33, pp. 42-44. , doi:10.1016/0090- 4295(89)90105-2 | |
| dc.description | Fujii, Y., Yonese, J., Kawakami, S., Yamamoto, S., Okubo, Y., Fukui, I., Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer (2008) BJU International, 101, pp. 1096-1100. , doi:10.1111/j.1464-410X.2007.07374.x | |
| dc.description | Heyns, C.F., Simonin, M.P., Grosgurin, P., Schall, R., Porchet, H.C., Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer (2003) BJU International, 92, pp. 226-231. , South African Triptorelin Study Group (doi:10.1046/j.1464-410X.2003. 04308.x) | |
| dc.description | Hussain, M., Tangen, C.M., Higano, C., Schelhammer, P.F., Faulkner, J., Crawford, E.D., Wilding, G., Donnelly, B., Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162) (2006) Journal of Clinical Oncology, 24, pp. 3984-3990. , doi:10.1200/JCO.2006.06.4246 | |
| dc.description | Kaisary, A.V., Tyrrell, C.J., Peeling, W.B., Griffiths, K., Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma (1991) British Journal of Urology, 67, pp. 502-508. , doi:10.1111/ j.1464-410X.1991.tb15195.x | |
| dc.description | Lawrentschuk, N., Fernandes, K., Bell, D., Barkin, J., Fleshner, N., Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence (2011) Journal of Urology, 185, pp. 848-854. , doi:10.1016/j.juro.2010.10.055 | |
| dc.description | Marberger, M., Kaisary, A.V., Shore, N.D., Karlin, G.S., Savulsky, C., Mis, R., Leuratti, C., Germa, J.R., Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: A phase III, open-label, International Multicenter Study (2010) Clinical Therapeutics, 32, pp. 744-757. , doi:10.1016/ j.clinthera.2010.04.013 | |
| dc.description | Messing, E.M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E.D., Trump, D., Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer (1999) New England Journal of Medicine, 341, pp. 1781-1788. , doi:10.1056/NEJM199912093412401 | |
| dc.description | Morote, J., Orsola, A., Planas, J., Trilla, E., Raventós, C.X., Cecchini, L., Catalán, R., Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy (2007) Journal of Urology, 178, pp. 1290-1295. , doi:10.1016/j.juro.2007.05.129 | |
| dc.description | Morote, J., Planas, J., Salvador, C., Raventós, C.X., Catalán, R., Reventós, J., Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy (2009) BJU International, 103, p. 332. , doi:10.1111/j.1464-410X.2008.08062.x | |
| dc.description | Oefelein, M.G., Feng, A., Scolieri, M.J., Ricchiutti, D., Resnick, M.I., Reassessment of the definition of castrate levels of testosterone: Implications for clinical decision making (2000) Urology, 56, p. 1021. , doi:10.1016/S0090-4295(00)00793-7 | |
| dc.description | Perachino, M., Cavalli, V., Testosterone (T) level correlates with survival in pts with advanced prostate cancer (APC): The lower is really the better (2008) Journal of Urology, 179, p. 179. , doi:10.1016/S0022-5347(08)60520-0 | |
| dc.description | Perachino, M., Cavalli, V., Bravi, F., Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: Prognostic significance? (2010) BJU International, 105, p. 648. , doi:10.1111/j.1464-410X.2009.08814.x | |
| dc.description | Pilepich, M.V., Winter, K., Lawton, C.A., Krisch, R.E., Wolkov, H.B., Movsas, B., Hug, E.B., Grignon, D., Androgen suppression adjuvant to definitive radiotherapy in carcinomas of the prostate - Long term results of phase III RTOG85-31 (2005) International Journal of Radiation Oncology, Biology, Physics, 61, pp. 1285-1290. , doi:10.1016/j.ijrobp.2004. 08.047 | |
| dc.description | Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials (2000) Lancet, 355, p. 1491. , Prostate Cancer Trialists' Collaborative Group (doi:10.1016/S0140- 6736(00)02163-2) | |
| dc.description | Reis, L.O., Old issues and new perspectives on prostate cancer hormonal therapy: The molecular substratum (2011) Medical Oncology, , in press. (doi:10.1007/s12032-011- 9991-z;PMID:21626233) | |
| dc.description | Reis, L.O., Vieira, L.F., Zani, E.L., Denardi, F., De Oliveira, L.C., Ferreira, U., Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer (2010) Journal of Investigative Medicine, 58, pp. 957-960. , doi:10.231/JIM. 0b013e3181f5d610 | |
| dc.description | Scher, H.I., Liebertz, C., Kelly, W.K., Mazumdar, M., Brett, C., Schwartz, L., Kolvenbag, G., Schwartz, M., Bicalutamide for advanced prostate cancer: The natural versus treated history of disease (1997) Journal of Clinical Oncology, 15 (8), pp. 2928-2938 | |
| dc.description | Schmitt, B., Bennett, C., Seidenfeld, J., Samson, D., Wilt, T., Maximal androgen blockade for advanced prostate cancer (2000) Cochrane Database of Systematic Reviews, 2. , CD001526. (doi:10.1002/14651858.CD001526) | |
| dc.description | Scholz, M., Lam, R., Strum, S., Jennrich, R., Johnson, H., Trilling, T., Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone- inactivating pharmaceuticals (2007) Urology, 70, pp. 506-510. , doi:10.1016/ j.urology.2007.04.015 | |
| dc.description | Seidenfeld, J., Samson, D.J., Hasselblad, V., Aronson, N., Albertsen, P.C., Bennett, C.L., Wilt, T.J., Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis (2000) Annals of Internal Medicine, 132 (7), pp. 566-577 | |
| dc.description | Sharifi, R., Bruskewitz, R.C., Gittleman, M.C., Graham Jr., S.D., Hudson, P.B., Stein, B., Leuprorelin acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer (1996) Clinical Therapeutics, 18, p. 647. , doi:10.1016/S0149-2918(96)80215-3 | |
| dc.description | Silva, E.D., Ferreira, U., Matheus, W., Faria, E.F., Silva, G.D., Saito, M., Goserelin versus leuprolide in the chemical castration of patients with prostate cancer (2012) International Urology and Nephrology, , [in press]. doi:10.1007/s11255- 012-0134-z;PMID:22315155 | |
| dc.description | Smith, M.R., Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer (2007) Clinical Cancer Research, 13, p. 241. , doi:10.1158/1078-0432. CCR-06-2086 | |
| dc.description | Smith, M., McGovern, F., Gonadotropin releasing hormone agonist failure in a man with prostate cancer (2001) Journal of Urology, 166, p. 211. , doi:10.1016/S0022- 5347(05)66115-0 | |
| dc.description | Suzuki, H., Okihara, K., Miyake, H., Fujisawa, M., Miyoshi, S., Matsumoto, T., Fujii, M., Matsuda, T., Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade (2008) Journal of Urology, 180, pp. 921-927. , doi:10.1016/j.juro.2008.05.045 | |
| dc.description | Tanaka, N., Fujimoto, K., Hirao, Y., Shimizu, K., Tsujimoto, S., Samma, S., Endocrine response to a single injection of goserelin 3.6 mg or leuprolide 3.75 mg in men with prostate cancer (2007) Archives of Andrology, 53, p. 289. , doi:10.1080/01485010701601222 | |
| dc.description | Tombal, B., Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: What is the optimal level of testosterone (2005) European Urology Supplements, 4 (5), pp. 14-19. , doi:10.1016/j.eursup.2005.04.004 | |
| dc.description | Vogelzang, N.J., Chodak, G.W., Soloway, M.S., Block, N.L., Schellhammer, P.F., Smith Jr., J.A., Caplan, R.J., Kennealey, G.T., Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial (1995) Urology, 46, pp. 220-226. , Zoladex Prostate Study Group. doi:10.1016/S0090-4295(99)80197-6 | |
| dc.description | Wheeler, M.J., D'Souza, A., Matadeen, J., Croos, P., Ciba Corning ACS: 180 Testosterone assay evaluated (1996) Clinical Chemistry, 42, p. 1445 | |
| dc.description | Wilke, T.J., Utley, D.J., Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and otherwise normal women with altered binding of sex-hormone binding globulin (1987) Clinical Chemistry, 33, p. 1372 | |
| dc.description | Yri, O.E., Bjoro, T., Fossa, S.D., Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer (2006) European Urology, 49, p. 54. , doi:10.1016/j.eururo.2005.09.009 | |
| dc.description | Zherdev, A.V., Byzova, N.A., Izumrudov, V.A., Dzantiev, B.B., Rapid polyelectrolyte-based immunofiltration technique for testosterone detection in serum samples (2003) Analyst, 128, p. 1275. , doi:10.1039/b303288d | |
| dc.language | en | |
| dc.publisher | | |
| dc.relation | Endocrine-Related Cancer | |
| dc.rights | fechado | |
| dc.source | Scopus | |
| dc.title | Variations Of Serum Testosterone Levels In Prostate Cancer Patients Under Lh-releasing Hormone Therapy: An Open Question | |
| dc.type | Artículos de revistas | |
